Cannabinoid-based drugs as anti-inflammatory therapeutics

[1]  R. Hampson,et al.  Cannabinoid physiology and pharmacology: 30 years of progress , 2004, Neuropharmacology.

[2]  S. Burstein,et al.  Pain reduction and lack of psychotropic effects with ajulemic acid: comment on the article by Sumariwalla et al. , 2004, Arthritis & Rheumatism.

[3]  Georges J. M. Maestroni.  The endogenous cannabinoid 2‐arachidonoyl glycerol as in vivo chemoattractant for dendritic cells and adjuvant for Th1 response to a soluble protein , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  K. Waku,et al.  2‐Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces the migration of EoL‐1 human eosinophilic leukemia cells and human peripheral blood eosinophils , 2004, Journal of leukocyte biology.

[5]  C. Newton,et al.  The THC‐induced suppression of Th1 polarization in response to Legionella pneumophila infection is not mediated by increases in corticosterone and PGE2 , 2004, Journal of leukocyte biology.

[6]  V. Marzo,et al.  A new strategy to block tumor growth by inhibiting endocannabinoid inactivation , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  L. Petrocellis,et al.  The endocannabinoid system and its therapeutic exploitation , 2004, Nature Reviews Drug Discovery.

[8]  D. Wade,et al.  Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients , 2004, Multiple sclerosis.

[9]  C. Vaney,et al.  Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study , 2004, Multiple sclerosis.

[10]  Q. Pittman,et al.  Effects of cannabinoid receptor‐2 activation on accelerated gastrointestinal transit in lipopolysaccharide‐treated rats , 2004, British journal of pharmacology.

[11]  T. Jensen,et al.  Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial , 2004, BMJ : British Medical Journal.

[12]  B. Löwenberg,et al.  The peripheral cannabinoid receptor Cb2, frequently expressed on AML blasts, either induces a neutrophilic differentiation block or confers abnormal migration properties in a ligand-dependent manner. , 2004, Blood.

[13]  P. Pacher,et al.  Cannabinoids cool the intestine , 2004, Nature Medicine.

[14]  Shizuo Akira,et al.  Toll-like receptor signalling , 2004, Nature Reviews Immunology.

[15]  C. Piccirillo,et al.  Cornerstone of peripheral tolerance: naturally occurring CD4+CD25+ regulatory T cells. , 2004, Trends in immunology.

[16]  D. Ziedonis,et al.  Advances in pharmacotherapy for tobacco dependence. , 2004, Expert opinion on emerging drugs.

[17]  R. Pertwee,et al.  Cannabinoids and glaucoma , 2004, British Journal of Ophthalmology.

[18]  B. Cravatt,et al.  The endogenous cannabinoid system protects against colonic inflammation. , 2004, The Journal of clinical investigation.

[19]  R. Tuma,et al.  Win 55212-2, a cannabinoid receptor agonist, attenuates leukocyte/endothelial interactions in an experimental autoimmune encephalomyelitis model , 2004, Multiple sclerosis.

[20]  K. Waku,et al.  2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces accelerated production of chemokines in HL-60 cells. , 2004, Journal of biochemistry.

[21]  S. Black.  Cannabinoid receptor antagonists and obesity. , 2004, Current opinion in investigational drugs.

[22]  F. Rossi,et al.  Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia‐reperfusion injury: involvement of cytokine/chemokines and PMN , 2004, Journal of leukocyte biology.

[23]  M. Feldmann,et al.  A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. , 2004, Arthritis and rheumatism.

[24]  P. Sonneveld,et al.  Distinct Expression Profiles of the Peripheral Cannabinoid Receptor in Lymphoid Tissues Depending on Receptor Activation Status 1 , 2004, The Journal of Immunology.

[25]  Marlene Wolf,et al.  Chemokines: multiple levels of leukocyte migration control. , 2004, Trends in immunology.

[26]  Thomas W. Klein,et al.  Cannabinoid receptors and T helper cells , 2004, Journal of Neuroimmunology.

[27]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[28]  J. Zajicek,et al.  Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial , 2003, The Lancet.

[29]  M. Yamakuchi,et al.  Membrane cholesterol but not putative receptors mediates anandamide‐induced hepatocyte apoptosis , 2003, Hepatology.

[30]  D. Piomelli.  The molecular logic of endocannabinoid signalling , 2003, Nature Reviews Neuroscience.

[31]  A. Thompson,et al.  Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. , 2003, Brain : a journal of neurology.

[32]  C. Newton,et al.  The cannabinoid system and immune modulation , 2003, Journal of leukocyte biology.

[33]  M. Guzmán,et al.  Cannabinoids: potential anticancer agents , 2003, Nature Reviews Cancer.

[34]  E. Adler-Graschinsky,et al.  Cannabinoid system as a potential target for drug development in the treatment of cardiovascular disease. , 2003, Current vascular pharmacology.

[35]  D. Cockayne,et al.  Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: Pain inhibition by receptors not present in the CNS , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[36]  N. Rothwell,et al.  Endogenous Interleukin-1 Receptor Antagonist Mediates Anti-Inflammatory and Neuroprotective Actions of Cannabinoids in Neurons and Glia , 2003, The Journal of Neuroscience.

[37]  J. Erb-Downward,et al.  Production of Eicosanoids and Other Oxylipins by Pathogenic Eukaryotic Microbes , 2003, Clinical Microbiology Reviews.

[38]  K. Nicolay,et al.  Neuroprotection by the Endogenous Cannabinoid Anandamide and Arvanil against In Vivo Excitotoxicity in the Rat: Role of Vanilloid Receptors and Lipoxygenases , 2003, The Journal of Neuroscience.

[39]  Hui Li,et al.  Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid. , 2003, Molecular pharmacology.

[40]  A. Thompson,et al.  The therapeutic potential of cannabis , 2003, The Lancet Neurology.

[41]  R. de la Torre,et al.  Modulation of the immune system in cannabis users. , 2003, JAMA.

[42]  D. Baker,et al.  The therapeutic potential of cannabis in multiple sclerosis , 2003, Expert opinion on investigational drugs.

[43]  J. Borrell,et al.  Therapeutic Action of Cannabinoids in a Murine Model of Multiple Sclerosis , 2003, The Journal of Neuroscience.

[44]  S. Burstein,et al.  Suppression of human monocyte interleukin-1beta production by ajulemic acid, a nonpsychoactive cannabinoid. , 2003, Biochemical pharmacology.

[45]  K. Mackie,et al.  Nonpsychotropic Cannabinoid Receptors Regulate Microglial Cell Migration , 2003, The Journal of Neuroscience.

[46]  E. Del Giudice,et al.  Cannabinoids ablate release of TNFα in rat microglial cells stimulated with lypopolysaccharide , 2003, Glia.

[47]  D. Lehmann,et al.  γ-Irradiation Enhances Apoptosis Induced by Cannabidiol, a Non-psychotropic Cannabinoid, in Cultured HL-60 Myeloblastic Leukemia Cells , 2003, Leukemia & lymphoma.

[48]  M. Roth,et al.  Δ9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells , 2002, Journal of Neuroimmunology.

[49]  Sebastian Spindeldreher,et al.  Clustering of MHC–peptide complexes prior to their engagement in the immunological synapse: lipid raft and tetraspan microdomains , 2002, Immunological reviews.

[50]  I. Matias,et al.  Presence and regulation of the endocannabinoid system in human dendritic cells. , 2002, European journal of biochemistry.

[51]  Tony Wyss-Coray,et al.  Inflammation in Neurodegenerative Disease—A Double-Edged Sword , 2002, Neuron.

[52]  M. Adler,et al.  Heterologous desensitization of opioid receptors by chemokines inhibits chemotaxis and enhances the perception of pain , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[53]  T. Bisogno,et al.  Endocannabinoids as physiological regulators of colonic propulsion in mice. , 2002, Gastroenterology.

[54]  M. Herkenham,et al.  International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors , 2002, Pharmacological Reviews.

[55]  J. Maffrand,et al.  Functional assessment of neuronal cannabinoid receptors in the muscular layers of human ileum and colon. , 2002, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[56]  N. Knoller,et al.  Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial. , 2002, Critical care medicine.

[57]  M. Maccarrone,et al.  Endocannabinoid degradation, endotoxic shock and inflammation. , 2002, Current drug targets. Inflammation and allergy.

[58]  K. Waku,et al.  Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. , 2002, Prostaglandins, leukotrienes, and essential fatty acids.

[59]  M. Glass,et al.  CB(1) and CB(2) receptor-mediated signalling: a focus on endocannabinoids. , 2002, Prostaglandins, leukotrienes, and essential fatty acids.

[60]  R. Mechoulam,et al.  Cannabinoids and brain injury: therapeutic implications. , 2002, Trends in molecular medicine.

[61]  M. Kathmann,et al.  Modulation of transmitter release via presynaptic cannabinoid receptors. , 2001, Trends in pharmacological sciences.

[62]  S. Ben-Shabat,et al.  An endogenous cannabinoid (2-AG) is neuroprotective after brain injury , 2001, Nature.

[63]  R. Capasso,et al.  Cannabinoid CB1‐receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation , 2001, British journal of pharmacology.

[64]  L. Petrocellis,et al.  Lipopolysaccharide downregulates fatty acid amide hydrolase expression and increases anandamide levels in human peripheral lymphocytes. , 2001, Archives of biochemistry and biophysics.

[65]  G. Denhardt,et al.  Modulation of cytokine responses in Corynebacterium parvum-primed endotoxemic mice by centrally administered cannabinoid ligands. , 2001, European journal of pharmacology.

[66]  H. Weiner,et al.  Induction and mechanism of action of transforming growth factor‐β‐secreting Th3 regulatory cells , 2001, Immunological reviews.

[67]  C. Newton,et al.  Differential expression of cannabinoid CB(2) receptor mRNA in mouse immune cell subpopulations and following B cell stimulation. , 2001, European journal of pharmacology.

[68]  C. Breivogel,et al.  Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. , 2001, Molecular pharmacology.

[69]  M. Yamakuchi,et al.  Simultaneous measurement of anandamide and 2-arachidonoylglycerol by polymyxin B-selective adsorption and subsequent high-performance liquid chromatography analysis: increase in endogenous cannabinoids in the sera of patients with endotoxic shock. , 2001, Analytical biochemistry.

[70]  M. Christie,et al.  Neurobiology: Cannabinoids act backwards , 2001, Nature.

[71]  Z. Vogel,et al.  2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[72]  B. Kelsall,et al.  Regulation of interleukin-12 production by G-protein-coupled receptors. , 2001, Microbes and infection.

[73]  T. Bisogno,et al.  Endocannabinoids control spasticity in a multiple sclerosis model , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[74]  E. Berdyshev,et al.  Cannabinoid receptors and the regulation of immune response. , 2000, Chemistry and physics of lipids.

[75]  C. Newton,et al.  Anti-CD40, anti-CD3, and IL-2 stimulation induce contrasting changes in CB1 mRNA expression in mouse splenocytes , 2000, Journal of Neuroimmunology.

[76]  M. Feldmann,et al.  The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[77]  Li Zhu,et al.  Δ-9-Tetrahydrocannabinol Inhibits Antitumor Immunity by a CB2 Receptor-Mediated, Cytokine-Dependent Pathway1 , 2000, The Journal of Immunology.

[78]  C. Newton,et al.  Δ9-Tetrahydrocannabinol Treatment Suppresses Immunity and Early IFN-γ, IL-12, and IL-12 Receptor β2 Responses to Legionella pneumophila Infection1 , 2000, The Journal of Immunology.

[79]  G. Denhardt,et al.  Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice. , 2000, The Journal of pharmacology and experimental therapeutics.

[80]  R. Pertwee,et al.  Cannabinoids control spasticity and tremor in a multiple sclerosis model , 2000, Nature.

[81]  M. Cortés,et al.  Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation , 2000, Nature Medicine.

[82]  N. Kaminski,et al.  Cannabinol-mediated inhibition of nuclear factor-kappaB, cAMP response element-binding protein, and interleukin-2 secretion by activated thymocytes. , 1999, The Journal of pharmacology and experimental therapeutics.

[83]  M. S. Taylor,et al.  1',1'-Dimethylheptyl-delta-8-tetrahydrocannabinol-11-oic acid: a novel, orally effective cannabinoid with analgesic and anti-inflammatory properties. , 1999, The Journal of pharmacology and experimental therapeutics.

[84]  T. Kawai,et al.  Selective diapedesis of Th1 cells induced by endothelial cell RANTES. , 1999, Journal of immunology.

[85]  L. Petrocellis,et al.  Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. , 1999, European journal of biochemistry.

[86]  D. Julius,et al.  Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide , 1999, Nature.

[87]  S. Burstein,et al.  The cannabinoid acids: nonpsychoactive derivatives with therapeutic potential. , 1999, Pharmacology & therapeutics.

[88]  A. Doble.  The role of excitotoxicity in neurodegenerative disease: implications for therapy. , 1999 .

[89]  G. Kunos,et al.  Platelet‐ and macrophage‐derived endogenous cannabinoids are involved in endotoxin‐induced hypotension , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[90]  C. Newton,et al.  Cannabinoid receptors and immunity. , 1998, Immunology today.

[91]  D. Piomelli,et al.  Control of pain initiation by endogenous cannabinoids , 1998, Nature.

[92]  L. Petrocellis,et al.  The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[93]  G. Cabral,et al.  Drugs and immunity: cannabinoids and their role in decreased resistance to infectious disease , 1998, Journal of Neuroimmunology.

[94]  A. Biegon,et al.  Protection against septic shock and suppression of tumor necrosis factor alpha and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid. , 1997, The Journal of pharmacology and experimental therapeutics.

[95]  A. N. Park,et al.  Marijuana and cocaine impair alveolar macrophage function and cytokine production. , 1997, American journal of respiratory and critical care medicine.

[96]  W. Kingery,et al.  A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes , 1997, Pain.

[97]  Z. Vogel,et al.  Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase. , 1997, Journal of medicinal chemistry.

[98]  T. Ben-Hur,et al.  Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-α inhibitor and an effective neuroprotectant , 1997, Journal of Neuroimmunology.

[99]  V. Di Marzo,et al.  Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. , 1996, The Biochemical journal.

[100]  Y. Daaka,et al.  Cannabinoid receptor proteins are increased in Jurkat, human T-cell line after mitogen activation. , 1996, The Journal of pharmacology and experimental therapeutics.

[101]  Y. Daaka,et al.  Δ9-Tetrahydrocannabinol, Cytokines, and Immunity to Legionella pneumophila , 1995, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[102]  Z. Vogel,et al.  Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. , 1995, Biochemical pharmacology.

[103]  R. Mechoulam,et al.  Suppression of experimental autoimmune encephalomyelitis by cannabinoids. , 1994, Immunopharmacology.

[104]  Y. Daaka,et al.  delta 9-Tetrahydrocannabinol enhances the secretion of interleukin 1 from endotoxin-stimulated macrophages. , 1994, The Journal of pharmacology and experimental therapeutics.

[105]  C. Newton,et al.  Secondary immunity to Legionella pneumophila and Th1 activity are suppressed by delta-9-tetrahydrocannabinol injection , 1994, Infection and immunity.

[106]  G. Cabral,et al.  Delta 9-tetrahydrocannabinol inhibition of tumor necrosis factor-alpha: suppression of post-translational events. , 1993, The Journal of pharmacology and experimental therapeutics.

[107]  C. Newton,et al.  Delta 9-tetrahydrocannabinol injection induces cytokine-mediated mortality of mice infected with Legionella pneumophila. , 1993, The Journal of pharmacology and experimental therapeutics.

[108]  S. Munro,et al.  Molecular characterization of a peripheral receptor for cannabinoids , 1993, Nature.

[109]  D. Gibson,et al.  Isolation and structure of a brain constituent that binds to the cannabinoid receptor. , 1992, Science.

[110]  T. Bonner,et al.  Structure of a cannabinoid receptor and functional expression of the cloned cDNA , 1990, Nature.

[111]  C. Brosnan,et al.  Δ 9-Tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis , 1989, Journal of Neuroimmunology.

[112]  G. Cabral,et al.  Δ9-Tetrahydrocannabinol Decreases Alpha/Beta Interferon Response to Herpes Simplex Virus Type 2 in the B6C3F1 Mouse 1 , 1986, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[113]  R. Mechoulam,et al.  Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish , 1964 .

[114]  C. Newton,et al.  Newton, C. A. et al. The THC-induced suppression of TH1 polarization in response to Legionella pneumophila infection is not mediated by increases in corticosterone and PGE2. J. Leukoc. Biol. 76, 854-861 , 2004 .

[115]  S. Miller,et al.  Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212. , 2003, The Journal of clinical investigation.

[116]  G. Cabral,et al.  Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. , 2002, International immunopharmacology.

[117]  Wan-Wan Lin,et al.  Effects of cannabinoids on LPS‐stimulated inflammatory mediator release from macrophages: Involvement of eicosanoids , 2001, Journal of cellular biochemistry.

[118]  Prabir Ray,et al.  A critical role for NF-κB in Gata3 expression and TH2 differentiation in allergic airway inflammation , 2001, Nature Immunology.

[119]  F. Wong,et al.  IFN- Affects Homing of Diabetogenic T Cells , 2001 .

[120]  C. Newton,et al.  The cannabinoid system and cytokine network. , 2000, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[121]  Li Zhu,et al.  D-9-Tetrahydrocannabinol Inhibits Antitumor Immunity by a CB2 Receptor-Mediated, Cytokine-Dependent Pathway , 2000 .

[122]  S. Burstein,et al.  Dimethylheptyl-THC-11-oic Acid , 1999 .

[123]  S. Burstein,et al.  Dimethylheptyl-THC-11 oic acid: a nonpsychoactive antiinflammatory agent with a cannabinoid template structure. , 1998, Arthritis and rheumatism.

[124]  C. Newton,et al.  In vitro and in vivo suppressive effects of delta-9-tetrahydrocannabinol on interferon production by murine spleen cells. , 1986, International journal of immunopharmacology.